LGMD: ICD-10 codes

ICD-10 Code	Subtype, if applicable	Description
G71.031	LGMD1/D	Autosomal dominant LGMD
G71.032	LGMD2A/R1	Autosomal recessive LGMD due to calpain-3 dysfunction (calpainopathy)
G71.033	LGMD2B/R2	LGMD due to dysferlin dysfunction (dysferlinopathy)
G71.0340		LGMD due to sarcoglycan dysfunction, unspecified (sarcoglycanopathy)
G71.0341	LGMD2D/R3	LGMD due to alpha sarcoglycan dysfunction (alpha-sarcoglycanopathy)
G71.0342	LGMD2E/R4	LGMD due to beta sarcoglycan dysfunction (beta-sarcoglycanopathy)
G71.0349	LGMD2C/R5* LGMD2F/R6*	LGMD due to other sarcoglycan dysfunction
G71.035	LGMD2L/R12	LGMD due to anoctamin-5 dysfunction (anoctaminopathy)
G71.038		Other LGMD**
G71.039		LGMD, unspecified***

^{*}LGMD2C/R5 is caused by mutations in the SGCG gene, which encodes gammasarcoglycan. LGMD2F/R6 is caused by mutations in the SGCD gene, which encodes delta-sarcoglycan.

^{**}G71.038 is intended for all other forms of autosomal recessive LGMD, such as LGMD2I/R9 (caused by mutations in fukutin-related protein gene, FKRP).

^{***}G71.039 is intended for patients that do not have a genetically confirmed LGMD diagnosis. If a patient has not yet received genetic testing to confirm their LGMD diagnosis, please visit limbgirdle.com/genetic-testing for more information.

Limb-Girdle Muscular Dystrophy: ICD-10 codes



©2023 Sarepta Therapeutics, Inc. 215 First Street, Cambridge, MA 02142. All rights reserved.

12/23 C-NP-US-2725

SAREPTA, SAREPTA THERAPEUTICS, and the SAREPTA Helix Logo are trademarks of Sarepta Therapeutics, Inc. registered in the U.S. Patent and Trademark Office and may be registered in various other jurisdictions.